Kura Oncology (KURA) Other Non-Current Assets (2014 - 2026)
Kura Oncology (KURA) reported Other Non-Current Assets of $14.0 million for Q1 2026, up 54.09% year-over-year from $9.1 million in Q1 2025, and down 3.8% on a QoQ basis from $14.5 million in Q4 2025.
Kura Oncology (KURA) has 13 years of Other Non-Current Assets data on file, last reported at $14.0 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 54.09% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 million (up 54.09% YoY) and the FY2025 annual result came in at $14.5 million, up 85.38% from the prior year.
- Other Non-Current Assets declined to $14.0 million in Q1 2026 per KURA's latest filing, from $14.5 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $14.5 million in Q4 2025 and bottomed at $210000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $7.6 million (2023), against an average of $6.7 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets changed 0.0%; it then jumped 3550.48% in 2024.
- Tracing KURA's Other Non-Current Assets over 5 years: stood at $3.5 million in 2022, then soared by 117.32% to $7.6 million in 2023, then increased by 3.2% to $7.8 million in 2024, then surged by 85.38% to $14.5 million in 2025, then slipped by 3.8% to $14.0 million in 2026.
- Per Business Quant, the three latest KURA Other Non-Current Assets figures stand at $14.0 million (Q1 2026), $14.5 million (Q4 2025), and $13.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | 13.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.99 Mn |
| Dec 31, 2025 | 14.54 Mn |
| Sep 30, 2025 | 13.78 Mn |
| Jun 30, 2025 | 10.57 Mn |
| Mar 31, 2025 | 9.08 Mn |
| Dec 31, 2024 | 7.85 Mn |
| Sep 30, 2024 | 8.23 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Mar 31, 2024 | 7.67 Mn |
| Dec 31, 2023 | 7.60 Mn |
| Sep 30, 2023 | 4.52 Mn |
| Jun 30, 2023 | 3.70 Mn |
| Mar 31, 2023 | 210,000.00 |
| Dec 31, 2022 | 3.50 Mn |
| Sep 30, 2022 | 210,000.00 |
| Jun 30, 2022 | 210,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Dec 31, 2021 | 3.31 Mn |
| Sep 30, 2021 | 210,000.00 |
| Jun 30, 2021 | 210,000.00 |
| Mar 31, 2021 | 210,000.00 |
| Dec 31, 2020 | 210,000.00 |
| Sep 30, 2020 | 1.63 Mn |
| Jun 30, 2020 | 210,000.00 |
| Mar 31, 2020 | 210,000.00 |
| Dec 31, 2019 | 2.09 Mn |
| Sep 30, 2019 | 1.52 Mn |
| Jun 30, 2019 | 1.59 Mn |
| Mar 31, 2019 | 1.77 Mn |
| Dec 31, 2018 | 1.18 Mn |
| Sep 30, 2018 | 1.11 Mn |
| Jun 30, 2018 | 1.09 Mn |
| Mar 31, 2018 | 1.09 Mn |
| Dec 31, 2017 | 1.20 Mn |
| Sep 30, 2017 | 1.18 Mn |
| Jun 30, 2017 | 1.09 Mn |
| Mar 31, 2017 | 1.26 Mn |
| Dec 31, 2016 | 971,000.00 |
| Sep 30, 2016 | 542,000.00 |
| Jun 30, 2016 | 268,000.00 |
| Mar 31, 2016 | 240,000.00 |
| Dec 31, 2015 | 319,000.00 |
| Sep 30, 2015 | 438,000.00 |
| Jun 30, 2015 | 279,000.00 |
| Mar 31, 2015 | 150,000.00 |
| Dec 31, 2014 | 150,000.00 |